BioSpace News Archive

Affimed Announces Pricing of Upsized $90 Million Public Offering of Common Shares

Affimed N.V. announced the pricing of its previously announced public offering of 22,500,000 of its common shares at a public offering price of $4.00 per common share.

April 12, 2022
·
4 min read
Policy

AffaMed Therapeutics Announces New Drug Approval for DEXTENZA in Macau for the Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery

AffaMed Therapeutics, a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative pharmaceutical, digital and surgical products, announced that DEXTENZA has been approved in Macau, China for the treatment of ocular inflammation and pain following ophthalmic surgery.

April 12, 2022
·
3 min read
Drug Development

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial of MN-166 (ibudilast) in Hospitalized COVID-19 Patients at Risk for Acute Respiratory Distress Syndrome

MediciNova, Inc. announced that the Phase 2 clinical trial of MN-166 in hospitalized COVID-19 patients at risk for developing acute respiratory distress syndrome has completed enrollment.

April 12, 2022
·
6 min read
Biotech Beach

Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering - Apr 13, 2022

Crinetics Pharmaceuticals, Inc. announced the pricing of an underwritten follow-on offering of 5,625,563 shares of its common stock at a price to the public of $22.22 per share.

April 12, 2022
·
5 min read